Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Business Wire
- Veteran biopharmaceutical executive from GSK and Eli Lilly brings more than 30 years of experience to Sarepta’s Board CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its Board of Directors. Ms. Connelly is a well-regarded executive with more than 30 years of experience in the pharmaceutical industry. Following Connelly’s appointment, Sarepta’s Board will comprise nine directors, eight of whom are independent.“Ms. Connelly is a seasoned board leader with extensive operating experience in biopharma and we’re pleased to welcome her to the Sarepta Board of Directors as we work to deliver on our strategy to bring transformative therapies to patients with rare diseases,” said M. Kathleen Behrens, Ph.D., Chairperson of Sarepta’s Board of Directors.“It’s an honor to join Sarepta’s Board and contribute to the next phase of the Company’s growth,
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $181.00 price target on the stock.MarketBeat
- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target raised by analysts at UBS Group AG from $173.00 to $188.00. They now have a "buy" rating on the stock.MarketBeat
- High Growth Tech Stocks to Watch in September 2024 [Yahoo! Finance]Yahoo! Finance
- High Growth Tech And 2 Other Promising Stocks For Your Portfolio [Yahoo! Finance]Yahoo! Finance
- High Growth Tech Stocks To Watch In September 2024 [Yahoo! Finance]Yahoo! Finance
SRPT
Earnings
- 8/7/24 - Beat
SRPT
Sec Filings
- 9/16/24 - Form 4
- 9/16/24 - Form 3
- 9/16/24 - Form 8-K
- SRPT's page on the SEC website